Two therapy sessions now buy something other than therapy. An employee whose employer sponsors sessions through Spring Health can give up two of them for a year of Big Health’s Sleepio, a digital program for poor sleep, or Daylight, Big Health’s program for worry and anxiety. Three of a dependent’s sessions buy a year of Mightier, a game-based emotional regulation program for children aged 6 to 14.

Spring announced the program, Care Marketplace, on November 16, describing it as more support “within the mental health benefit employers already offer.” It is available to eligible members of participating U.S. customers, and availability may vary by benefit.

The session has become a price

“Care Marketplace has no separate fee, contract or implementation cost for customers. Members can choose to exchange their employer-sponsored therapy sessions for access to these tools, billed upon enrollment at the session rate already in their contract.”

ORIGINAL REPORTING · SPRING HEALTH TO BEHAVIORAL WIRE

That answer settles what the launch release left open. The employer is not buying Sleepio under a separate contract; enrollment is billed using the session rate already in its Spring contract. The member, not the benefits buyer, decides whether sponsored sessions go to a clinician or to a year of a digital program.

The session now does two jobs. It is still a clinical entitlement, a visit with a therapist. Its contracted rate is also the basis on which other forms of care inside the same benefit are billed. An employer that wanted Sleepio before had to select it, contract for it and pay for it as its own line item. Under Care Marketplace, the selection happens member by member, inside an allotment the employer has already funded, and the billing basis is the session rate the employer already agreed.

Spring did more than add a sleep app. It made the therapy-session entitlement transferable across forms of care.

Why sleep went first

Spring chose its first categories with its own survey data behind them. In its 2026 workplace report, released in April, 36 percent of employees named sleep as a top mental health challenge over the past year, against 21 percent of HR leaders, who ranked it fifth. These are Spring-reported results from a survey of more than 2,000 HR leaders and employees in five countries; Spring has not published the split between the two groups or the question wording. Sleep also led narrowly: chronic stress was named by 35 percent of employees and anxiety by 32 percent.

Sleep is therefore a useful test of whether members will spend part of a therapy entitlement on self-guided specialty care instead.

What early access shows, and what it does not

Spring has released two early-access figures. They answer different questions and should be read separately.

The first is about who signed up. Among 79 early-access enrollees from May through September, Spring says 87 percent had not previously been in therapy. Spring describes them as first-time care seekers, but the measure it reported is narrower: prior therapy, not prior care of any kind. The figure describes the people who enrolled. It does not show that they would otherwise have gone without care, that the Marketplace caused them to engage, or that Spring’s therapy offering had failed to reach them.

The second is about outcomes, and it is company-reported early-access data, not an efficacy study. At one early-access customer, a financial-services company, Spring says 73 percent of 46 participating members were classified as improved over a three-month observation period, based on baseline and reassessment scores. Sleepio users were measured on the SCI-2, a two-item version of the Sleep Condition Indicator that scores sleep symptoms, and Daylight users on the GAD-2, a two-item anxiety screening questionnaire.

There was no comparison group, so the change cannot be separated from natural recovery or from the tendency of people who enroll at a bad moment to report improvement later. Spring has not given the threshold for “improved,” the split between Sleepio and Daylight users, or how many of the 46 completed the reassessment. The last point bears on the headline number: no whole number out of 46 rounds conventionally to 73 percent (33 is 72 percent, 34 is 74 percent), so the figure may rest on a smaller group, such as those who were reassessed, or on another calculation.

What Spring has not disclosed

The billing answer covers the employer’s side of the exchange. The partner side remains undisclosed. Spring has not said what it pays Big Health or Mightier; whether partners are paid per enrollment, per activation, through a fixed arrangement or some other way; or whether Spring retains any difference between the session value billed to the employer and what it pays the program vendor.

Spring makes a different case. It argues that Care Marketplace lowers employer costs in two ways: earlier, lower-cost intervention that addresses everyday problems before they escalate into higher-acuity care, and downstream medical and workforce savings from keeping members connected to the right level of care. It points to cost studies of its broader behavioral-health program, including a peer-reviewed analysis in JAMA Network Open and a two-year Validation Institute analysis. Those studies evaluate Spring’s program as a whole. They do not isolate Care Marketplace or the economics of exchanging therapy sessions for digital programs.

For the employer, the trade is visible in sessions but not in dollars. From public information, it cannot see what a year of Sleepio costs Spring, and so cannot compare what it is billed for an enrollment with what the same program costs elsewhere. Members, meanwhile, give up sponsored sessions that would otherwise have been available for therapy that year. The size of that trade-off cannot be assessed from public information, because Spring has not disclosed the typical number of sponsored sessions across participating employer plans.

What the Sleepio evidence covers

The Sleepio offered through Care Marketplace is Big Health’s non-prescription program. Big Health’s own product page says it “has not been reviewed or approved by the Food & Drug Administration” and is not intended to diagnose or treat any medical condition.

A separate product, SleepioRx, is FDA-cleared. The FDA cleared it in August 2024 through the 510(k) pathway, which clears a device as substantially equivalent to one already legally marketed, as a prescription digital treatment for chronic insomnia, used as an adjunct to usual care in adults 18 and older. Big Health says SleepioRx was developed from Sleepio. Neither company has published whether the two share the same software and content, and the prescription product’s regulatory status does not carry over to the non-prescription version.

The two figures Spring cites for Sleepio come from studies whose scope is narrower than the launch wording:

  • “Meaningful improvement in sleep for 76% of users.” The figure traces to a 2012 randomized trial in the journal Sleep of 164 UK adults recruited and screened online. At the end of treatment, 76 percent of the digital CBT arm had a diary-measured sleep efficiency above 80 percent, against 29 percent on a placebo program and 18 percent on usual care. That is a sleep-efficiency threshold, not remission. Two authors held leadership roles at Sleepio, and one was a shareholder.
  • “$2,083 in annual health plan savings per person.” The figure comes from a 2025 retrospective claims study funded by Big Health, which helped design it and drafted the manuscript. It compared 11,027 users with 10,770 matched insomnia patients on standard care, mostly medication. The paper reports the total and component estimates separately. Most of the reported difference came from pharmacy spending: $1,745 per person. Medical spending was $213 lower, but that difference was not statistically significant. The two groups’ baseline annual costs differed ($4,985 versus $8,444), and the authors describe the results as associations, not causal effects.

The claims study calls its product SleepioRx, but its users started the program between 2017 and 2022, before the August 2024 clearance. The public record does not establish whether that cohort used the same program now offered through Care Marketplace. It does establish that the savings were measured against people already being treated for insomnia, a different population from employees who choose a sleep program from a benefits menu.

None of this makes Sleepio a weak choice. Digital CBT for insomnia has a substantial evidence base, and NICE, which advises the NHS in England, recommends Sleepio as a cost-saving option for treating insomnia and insomnia symptoms in primary care for people who would otherwise be offered sleep hygiene advice or sleeping pills. For people who would be eligible for face-to-face CBT for insomnia, NICE recommends further research, because the evidence comparing the two is limited. The point is narrower: the numbers in the launch describe other populations and, in one case, a product described as SleepioRx.

From therapy access to care routing

Spring says Care Marketplace, Guide, launched in April, and Alma, the insurance-billing platform for independent clinicians it combined with on May 1, “work together to expand our continuum of care,” with members routed to options matched to their needs and acuity. In Behavioral Wire’s reading, Care Marketplace is the piece that extends the platform toward self-guided, lower-intensity care, inside a benefit the employer already buys.

That changes how a specialty vendor reaches employees. Employers could already buy these programs: Evernorth added Sleepio and Daylight to its digital health formulary in 2022, Lyra Health offered Calm in 2020 as an integration employers purchased separately, and benefit marketplaces from Personify Health and Transcarent let employers contract with behavioral-health point solutions. In each case the employer selects and pays, so a vendor such as Big Health has to win that purchasing decision. Inside Care Marketplace, Sleepio reaches the employee as an option within the existing benefit. Behavioral Wire identified no comparable session-exchange mechanism in the public materials reviewed across major employer behavioral-health platforms and benefit marketplaces. Private contract terms are not visible, so this is not a claim that Spring is first.

The therapy session has become a currency inside the employer benefit, and Care Marketplace expands what that currency can buy.